Patents Assigned to ZENYAKU KOGYO CO., LTD.
-
Publication number: 20240102992Abstract: A low-variation and highly reproducible method for measuring antibody-dependent cellular cytotoxicity activity of an antibody for a dog as the subject of administration is provided. A method for measuring antibody-dependent cellular cytotoxicity activity comprising a step of causing an antibody and cells in which a canine CD16-canine Fc? receptor ? chain fusion protein is expressed in human-derived NK cells to act on canine tumor-derived cells or cells which express a canine tumor antigen and a step of detecting the cell death of the canine tumor-derived cells or the cells which express the canine tumor antigen. Also, the method for measuring antibody-dependent cellular cytotoxicity activity in which the human-derived NK cells are NK-92 cells.Type: ApplicationFiled: August 8, 2023Publication date: March 28, 2024Applicant: NIPPON ZENYAKU KOGYO CO., LTD.Inventors: Takuya MIZUNO, Masaya Igase, Yoshiho Takeda
-
Patent number: 11492399Abstract: Provided is an antibody that has a high binding activity to membrane-bound IgM on the surface of B cells and exhibits a growth inhibition effect on the B cells, even in the presence of soluble IgM in blood. A bispecific antibody, which binds to IgM and a B cell surface antigen.Type: GrantFiled: March 23, 2018Date of Patent: November 8, 2022Assignee: ZENYAKU KOGYO CO., LTD.Inventors: Yasukatsu Tsukada, Takahiro Ohashi, Hitoshi Miyashita, Satoko Tatebe, Jumpei Enami
-
Publication number: 20220348676Abstract: To provide a monoclonal antibody against canine CD20 having a more excellent effect than existing antibodies. The present invention provides a monoclonal antibody or antibody fragment against canine CD20 that has a heavy chain variable region consisting of an amino acid sequence of SEQ ID NO: 1 or an amino acid sequence in which one or several amino acids are deleted, substituted, or added in the amino acid sequence of SEQ ID NO: 1, and a light chain variable region consisting of an amino acid sequence of SEQ ID NO: 2 or an amino acid sequence in which one or several amino acids are deleted, substituted, or added in the amino acid sequence of SEQ ID NO: 2, and that has a light chain constant region consisting of an amino acid sequence of SEQ ID NO: 3 or an amino acid sequence in which one or several amino acids are deleted, substituted, or added in the amino acid sequence of SEQ ID NO: 3.Type: ApplicationFiled: October 2, 2020Publication date: November 3, 2022Applicant: NIPPON ZENYAKU KOGYO CO., LTD.Inventor: Takuya MIZUNO
-
Patent number: 11104727Abstract: Provided are an anti-canine TARC antibody for use in the treatment and diagnosis of canine atopic dermatitis, and a method for treating or diagnosing canine atopic dermatitis using the same. An anti-canine TARC monoclonal antibody binding to canine TARC, comprising a heavy chain variable region consisting of the amino acid sequence shown in SEQ ID NO: 2 and a light chain variable region consisting of the amino acid sequence shown in SEQ ID NO: 4, or a functional fragment thereof binding to canine TARC.Type: GrantFiled: October 13, 2016Date of Patent: August 31, 2021Assignee: NIPPON ZENYAKU KOGYO CO., LTD.Inventors: Toshihiro Tsukui, Miyuki Kageyama, Masahiro Kato, Rieko Suzuki
-
Publication number: 20210163607Abstract: Provided are a treatment method and a therapeutic agent for canine tumor. A pharmaceutical composition for treating canine tumor, comprising, as an active ingredient, a compound that inhibits the binding of canine CCL17 and canine CCR4.Type: ApplicationFiled: April 26, 2018Publication date: June 3, 2021Applicant: NIPPON ZENYAKU KOGYO CO., LTD.Inventor: Shingo MAEDA
-
Patent number: 11013756Abstract: The present invention provides an anti-IL-17 aptamer comprising a compound represented by the following formula (I): (each symbol is as defined in the DESCRIPTION) or a pharmaceutically acceptable salt, solvate or hydrate thereof, and showing improved in vivo stability.Type: GrantFiled: December 2, 2016Date of Patent: May 25, 2021Assignee: ZENYAKU KOGYO CO., LTD.Inventors: Kazuhiko Haruta, Hiroaki Yamazaki
-
Publication number: 20200123248Abstract: Provided is an antibody that has a high binding activity to membrane-bound IgM on the surface of B cells and exhibits a growth inhibition effect on the B cells, even in the presence of soluble IgM in blood. A bispecific antibody, which binds to IgM and a B cell surface antigen.Type: ApplicationFiled: March 23, 2018Publication date: April 23, 2020Applicant: ZENYAKU KOGYO CO., LTD.Inventors: Yasukatsu TSUKADA, Takahiro OHASHI, Hitoshi MIYASHITA, Satoko TATEBE, Jumpei ENAMI
-
Publication number: 20190381088Abstract: The present invention provides an anti-IL-17 aptamer comprising a compound represented by the following formula (I): (each symbol is as defined in the DESCRIPTION) or a pharmaceutically acceptable salt, solvate or hydrate thereof, and showing improved in vivo stability.Type: ApplicationFiled: December 2, 2016Publication date: December 19, 2019Applicant: ZENYAKU KOGYO CO., LTD.Inventors: Kazuhiko HARUTA, Hiroaki YAMAZAKI
-
Patent number: 10428112Abstract: The present invention provides a synthetic peptide capable of inducing an antibody to an autoantigen, and specifically, provides: a multiplexed same type-antigenic peptide having a dendritic core and B-cell recognition peptides, wherein the multiplexed same type-antigenic peptide comprises 4 to 8 B-cell recognition peptides of the same type that are bound to the terminal ends of the dendritic core directly or via a spacer, and each B-cell recognition peptide is bound to the terminal end of the dendritic core directly or via a spacer; an antibody production-inducing agent having the peptides; and a method for producing the peptide.Type: GrantFiled: June 11, 2015Date of Patent: October 1, 2019Assignees: RIKEN, Animal Allergy Clinical Laboratories Inc., Nippon Zenyaku Kogyo Co., Ltd.Inventors: Kenichi Masuda, Yasuyuki Ishii, Toshihiro Tsukui
-
Patent number: 10280223Abstract: The object of the present invention is to provide an anti-canine PD-1 antibody or an anti-canine PD-L1 antibody, an agent for inhibiting binding between a canine PD-1 and a canine PD-L1 containing such an antibody, a method for inhibiting binding between a canine PD-1 and a canine PD-L1 comprising using such an antibody, and a gene encoding such an antibody. An anti-canine PD-1 antibody that specifically binds to a canine PD-1 consisting of the amino acid sequence set forth in SEQ ID NO: 1 and an anti-canine PD-L1 antibody that specifically binds to a canine PD-L1 consisting of the amino acid sequence set forth in SEQ ID NO: 6 are produced. An agent for inhibiting binding between a canine PD-1 and a canine PD-L1 containing such an antibody is also produced.Type: GrantFiled: July 8, 2015Date of Patent: May 7, 2019Assignee: NIPPON ZENYAKU KOGYO CO., LTD.Inventors: Takuya Mizuno, Kazuha Shosu
-
Publication number: 20180319879Abstract: Provided are an anti-canine TARC antibody for use in the treatment and diagnosis of canine atopic dermatitis, and a method for treating or diagnosing canine atopic dermatitis using the same. An anti-canine TARC monoclonal antibody binding to canine TARC, comprising a heavy chain variable region consisting of the amino acid sequence shown in SEQ ID NO: 2 and a light chain variable region consisting of the amino acid sequence shown in SEQ ID NO: 4, or a functional fragment thereof binding to canine TARC.Type: ApplicationFiled: October 13, 2016Publication date: November 8, 2018Applicant: NIPPON ZENYAKU KOGYO CO., LTD.Inventors: Toshihiro TSUKUI, Miyuki KAGEYAMA, Masahiro KATO, Rieko SUZUKI
-
Patent number: 9850317Abstract: Problem to be Solved: The present invention is intended to provide a polynucleotide encoding the light-chain variable region and the heavy-chain variable region of an anti-dog IgE antibody; and an anti-dog IgE antibody containing these variable regions. Solution: The present invention is DNA encoding a heavy-chain variable region consisting of the amino acid sequence represented by SEQ ID NO: 2 or 6 and DNA encoding a light-chain variable region consisting of the amino acid sequence represented by SEQ ID NO: 4 or 8, and an anti-dog IgE monoclonal antibody which binds to dog IgE, containing these variable regions or a functional fragment thereof which binds to dog IgE.Type: GrantFiled: March 17, 2014Date of Patent: December 26, 2017Assignees: KAZUSA DNA RESEARCH INSTITUTE, ANIMAL ALLERGY CLINICAL LABORATORIES INC., NIPPON ZENYAKU KOGYO CO., LTD.Inventors: Osamu Ohara, Takahiro Nagase, Yoshihiro Yamaguchi, Reiko Ohara, Kenichi Masuda, Toshihiro Tsukui
-
Patent number: 9732107Abstract: This invention provides a method of preparing a ?-hematin crystal comprising a step of heating, the ?-hematin crystal obtained by such method, and a vaccine adjuvant composition containing the ?-hematin crystal. The ?-hematin crystal has a needle-like morphology, it has an average particle size of 0.6 to 1.2 ?m, and it exhibits main peaks characteristics for angles of diffraction (2?) of 7.4°, 12.2°, 21.6°, and 24.1° in an X-ray diffraction pattern obtained by powder X-ray diffractometry with Cu—K? rays (with each peak including a plus-minus 0.2° diffraction angle).Type: GrantFiled: June 4, 2014Date of Patent: August 15, 2017Assignees: Osaka University, Nippon Zenyaku Kogyo Co., Ltd.Inventors: Shizuo Akira, Ken Ishii, Cevayir Coban, Yoshikatsu Igari, Yasumasa Kano, Akina Otsuki
-
Publication number: 20170158764Abstract: The object of the present invention is to provide an anti-canine PD-1 antibody or an anti-canine PD-L1 antibody, an agent for inhibiting binding between a canine PD-1 and a canine PD-L1 containing such an antibody, a method for inhibiting binding between a canine PD-1 and a canine PD-L1 comprising using such an antibody, and a gene encoding such an antibody. An anti-canine PD-1 antibody that specifically binds to a canine PD-1 consisting of the amino acid sequence set forth in SEQ ID NO: 1 and an anti-canine PD-L1 antibody that specifically binds to a canine PD-L1 consisting of the amino acid sequence set forth in SEQ ID NO: 6 are produced. An agent for inhibiting binding between a canine PD-1 and a canine PD-L1 containing such an antibody is also produced.Type: ApplicationFiled: July 8, 2015Publication date: June 8, 2017Applicant: NIPPON ZENYAKU KOGYO CO., LTD.Inventors: Takuya MIZUNO, Kazuha SHOSU
-
Patent number: 9657071Abstract: It is intended to provide an IgE peptide vaccine that can be used in the prevention or treatment of allergic diseases in animals other than mice, such as humans or dogs. The present invention provides a peptide consisting of (i) the amino acid sequence represented by SEQ ID NO: 28, or (ii) an amino acid sequence consisting of at least 10 consecutive amino acids in the amino acid sequence represented by SEQ ID NO: 28, wherein the peptide, when administered to an animal, is capable of specifically binding to a CH3 region in an IgE antibody of the animal and thereby blocking the binding of the IgE antibody to an IgE receptor.Type: GrantFiled: June 18, 2013Date of Patent: May 23, 2017Assignee: NIPPON ZENYAKU KOGYO CO., LTD.Inventor: Toshihiro Tsukui
-
Publication number: 20160272728Abstract: Problem to be Solved: The present invention is intended to provide a polynucleotide encoding the light-chain variable region and the heavy-chain variable region of an anti-dog IgE antibody; and an anti-dog IgE antibody containing these variable regions. Solution: The present invention is DNA encoding a heavy-chain variable region consisting of the amino acid sequence represented by SEQ ID NO: 2 or 6 and DNA encoding a light-chain variable region consisting of the amino acid sequence represented by SEQ ID NO: 4 or 8, and an anti-dog IgE monoclonal antibody which binds to dog IgE, containing these variable regions or a functional fragment thereof which binds to dog IgE.Type: ApplicationFiled: March 17, 2014Publication date: September 22, 2016Applicants: KAZUSA DNA RESEARCH INSTITUTE, NIPPON ZENYAKU KOGYO CO., LTD., ANIMAL ALLERGY CLINICAL LABORATORIES INC.Inventors: Osamu OHARA, Takahiro NAGASE, Yoshihiro YAMAGUCHI, Reiko OHARA, Kenichi MASUDA, Toshihiro TSUKUI
-
Publication number: 20160122378Abstract: This invention provides a method of preparing a ?-hematin crystal comprising a step of heating, the ?-hematin crystal obtained by such method, and a vaccine adjuvant composition containing the ?-hematin crystal. The ?-hematin crystal has a needle-like morphology, it has an average particle size of 0.6 to 1.2 ?m, and it exhibits main peaks characteristics for angles of diffraction (2?) of 7.4°, 12.2°, 21.6°, and 24.1° in an X-ray diffraction pattern obtained by powder X-ray diffractometry with Cu—K? rays (with each peak including a plus-minus 0.2° diffraction angle).Type: ApplicationFiled: June 4, 2014Publication date: May 5, 2016Applicants: OSAKA UNIVERSITY, NIPPON ZENYAKU KOGYO CO., LTD.Inventors: Shizuo AKIRA, Ken ISHII, Cevayir COBAN, Yoshikatsu IGARI, Yasumasa KANO, Akina OTSUKI
-
Patent number: 9056094Abstract: The present invention provides a vaccine adjuvant composition which is used in combination with an allergen vaccine, infection vaccine or tumor vaccine. The present invention specifically provides a vaccine adjuvant composition comprising hemozoin or ?-hematin and being used in combination with an allergen vaccine, infection vaccine or tumor vaccine, and a vaccine composition comprising the vaccine adjuvant composition and an allergen vaccine, infection vaccine or tumor vaccine.Type: GrantFiled: October 31, 2008Date of Patent: June 16, 2015Assignees: NIPPON ZENYAKU KOGYO CO., LTD., OSAKA UNIVERSITYInventors: Toshihiro Tsukui, Ken Ishii, Shizuo Akira, Cevayir Coban
-
Patent number: 8962705Abstract: A method for removing cauxin in cat urine and a material for removing cauxin are provided. The material for removing cauxin in cat urine comprises a polymer substrate on which surface a trifluoroketone derivative is immobilized via dithiol.Type: GrantFiled: February 17, 2011Date of Patent: February 24, 2015Assignees: National University Corporation Chiba University, Incorporated National University Iwate University, Nippon Zenyaku Kogyo Co., Ltd.Inventors: Shinya Matsuno, Kyoichi Saito, Tetsuro Yamashita, Ayako Ito, Yasuyuki Suzuta
-
Publication number: 20140080997Abstract: A safe and efficient recombinant mite allergen is provided as a therapeutic agent or a diagnostic agent for mite allergic diseases, which contains no anaphylaxis-inducing impurities. The following recombinant protein (a) or (b) is provided: (a) a protein comprising the amino acid sequence represented by SEQ ID NO: 2 or 35; or (b) a protein comprising an amino acid sequence derived from the amino acid sequence represented by SEQ ID NO: 2 or 35 by deletion, substitution, or addition of one or several amino acids and having mite allergen activity.Type: ApplicationFiled: October 14, 2013Publication date: March 20, 2014Applicant: NIPPON ZENYAKU KOGYO CO., LTD.Inventors: Toshihiro TSUKUI, Hajime TSUJIMOTO, Shigehiro IWABUCHI